GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » MedTech Acquisition Corp (NAS:MTACU) » Definitions » Cash Conversion Cycle

MedTech Acquisition (MedTech Acquisition) Cash Conversion Cycle : 0.00 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is MedTech Acquisition Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

MedTech Acquisition's Days Sales Outstanding for the three months ended in Jun. 2023 was .
MedTech Acquisition's Days Inventory for the three months ended in Jun. 2023 was .
MedTech Acquisition's Days Payable for the three months ended in Jun. 2023 was .
Therefore, MedTech Acquisition's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2023 was 0.00.


MedTech Acquisition Cash Conversion Cycle Historical Data

The historical data trend for MedTech Acquisition's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedTech Acquisition Cash Conversion Cycle Chart

MedTech Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Cash Conversion Cycle
- - -

MedTech Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MedTech Acquisition's Cash Conversion Cycle

For the Shell Companies subindustry, MedTech Acquisition's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedTech Acquisition's Cash Conversion Cycle Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where MedTech Acquisition's Cash Conversion Cycle falls into.



MedTech Acquisition Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

MedTech Acquisition's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=+-
=0.00

MedTech Acquisition's Cash Conversion Cycle for the quarter that ended in Jun. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedTech Acquisition  (NAS:MTACU) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


MedTech Acquisition Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of MedTech Acquisition's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


MedTech Acquisition (MedTech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
48 Maple Avenue, Greenwich, CT, USA, 06830
Website
MedTech Acquisition Corp is a blank check company.
Executives
Magnetar Financial Llc 10 percent owner 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Magnetar Capital Partners Lp 10 percent owner 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Supernova Management Llc 10 percent owner 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David J. Snyderman 10 percent owner C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David L Treadwell director 222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102
Manuel Aguero director 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Thierry B. Thaure director 3957 POINT EDEN WAY, HAYWARD CA 94545
David J Matlin director, 10 percent owner, officer: Chief Financial Officer
Karim Karti director C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Christopher C Dewey director, 10 percent owner, officer: Chief Executive Officer 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Robert H. Weiss officer: Chief Admin Officer and Sec. 585 WEED STREET, NEW CANAAN CT 06840
Maurice R Ferre director C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317
Ivan Delevic director C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317
Medtech Acquisition Sponsor Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Martin William Roche director 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022

MedTech Acquisition (MedTech Acquisition) Headlines

From GuruFocus